Related Experiment Video
Updated: Jun 27, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Pharmacogenetics in breast cancer therapy
Sing-Huang Tan1, Soo-Chin Lee, Boon-Cher Goh
1Department of Hematology-Oncology, National University of Singapore, National University Health System, Singapore, Singapore.
Summary
Genetic variations in drug-metabolizing enzymes and transporters influence drug response. Polymorphisms in genes like CYP2D6 affect tamoxifen efficacy, and further research is needed for other chemotherapy agents.
Area of Science:
- Pharmacogenetics
- Genomics
- Drug Metabolism
Background:
- Genetic polymorphisms in drug-metabolizing enzymes and transporters contribute to variable drug pharmacokinetics and pharmacodynamics.
- Interindividual and interethnic differences in these genetic variants impact drug efficacy and toxicity.
Purpose of the Study:
- To review the current understanding of genetic polymorphisms influencing the disposition and efficacy of various cancer therapeutics.
- To highlight the need for validation of findings from smaller studies in larger clinical trials.
Main Methods:
- Review of published literature on genetic polymorphisms related to tamoxifen, anthracyclines, taxanes, gemcitabine, capecitabine/5-fluorouracil, vinorelbine, and platinum agents.
- Discussion of candidate genes for targeted agents and future research directions.
Main Results:
- CYP2D6 polymorphisms significantly affect tamoxifen disposition and efficacy, with notable interethnic variations.
- Associations between polymorphisms in genes like CBR3, ABCB1, and oxidative stress genes and anthracycline outcomes have been reported.
- Earlier findings on taxane pharmacogenetics from small studies require validation in larger trials.
Conclusions:
- Genetic variability plays a crucial role in cancer drug response, necessitating pharmacogenetic approaches for personalized medicine.
- Future research should integrate multiple drug pathways to comprehensively analyze genetic factors influencing drug efficacy and toxicity.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...